Introduction/Background The study aims to investigate the clinical characteristics and prognostic factors of cervical cancer and estimate the 3-year survival rates.

Methodology A retrospective study was conducted on patients treated for cervical cancer in 2020. Three-year survival rates were analyzed using the Kaplan-Meier method and compared using the Log-rank test. Prognostic factors were assessed through Cox regression analysis.

Results Fifty-six patients were treated for cervical cancer, with a median age of 57 years [33–86]. The median age of first sexual intercourse was 20 years [15–30]. Ten patients had a history of sexually transmitted infections. The most frequent clinical stage was IIB in 40% of cases. All patients received pelvic radiotherapy (RT) at a dose of 45 Gy [30–64.8] in 25 fractions [10–36]. The spread of radiotherapy was less than 1.5 months in 87% of cases. Ninety-three per cent received concurrent chemotherapy with radiotherapy. Radiochemotherapy was well-tolerated in 90% of cases, and 20% of patients experienced anaemia during treatment. Seventy-seven per cent of patients underwent low-dose-rate uterovaginal brachytherapy. The total duration from the start of radiotherapy to the end of brachytherapy was 49 days [12–90]. Fifty-three per cent underwent surgery. Responses after neoadjuvant treatment were as follows: complete response in 50% of cases, partial response in 33% of cases, and progressive disease in 17% of cases. The 3-year overall survival (OS) and progression-free survival (PFS) were 73% and 63%, respectively. In a multivariate analysis, factors correlated with poor OS were age >50 years (p=0.016) and duration between the start of RT and the end of brachytherapy >30 days (p=0.001). Factors correlated with poor PFS were locally advanced tumour stage (p=0.03) and the absence of a complete response after surgery (p=0.0001).

Conclusion Cervical cancer remains a public health issue in our country, emphasizing the need for a mass screening program.

Disclosures No financial interest.